CYP2D6 and sickle cell disease: There is one report of clinical implementation of CYP2D6 genotyping for pediatric patients with sickle cell disease in order to provide genotype-guided therapy; clinical genetic testing coupled with decision support resulted in no patients with ultra-rapid or poor metabolizer genotypes being prescribed codeine [31].